<DOC>
	<DOCNO>NCT01786174</DOCNO>
	<brief_summary>The purpose study determine whether Gilenya , also know fingolimod , safe tolerable patient Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Gilenya Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>The primary objective study determine acute safety tolerability oral administration Gilenya ( fingolimod ) 0.5mg daily vs. match oral placebo administer daily . The primary outcome measure safety tolerability ; safety assess occurrence adverse event clinically meaningful change vital sign , ophthalmologic examination , physical examination , electrocardiogram standard clinical laboratory blood test , tolerability define ability subject complete entire 4-week study . The secondary outcome measure measure effect treatment circulate lymphocyte population patient ALS . Exploratory outcome measure include rate decline ALS Functional Rating Scale ( Revised ) ( ALSFRS-R ) Slow Vital Capacity ( VC ) course treatment . This study conduct subject meet El Escorial criterion possible , laboratory-supported probable , probable , definite criterion diagnosis ALS . At screening , eligible subject must least 18 year old , must SVC ≥ 65 % predict capacity age , height gender , must provide write informed consent prior screen . Subjects stable dose riluzole take riluzole , woman child-bearing age screen eligible inclusion long meet specific protocol requirement . Subjects remain randomized , placebo-controlled , double-blind treatment Week 4 visit . Each randomized subject also Week 8 Follow-up Telephone Interview assess adverse event ( AEs ) , change concomitant medication administer ALSFRS-R .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1 . Age 18 year old . 2 . Sporadic familial ALS diagnose possible , laboratorysupported probable , probable , definite define revise El Escorial criterion ( Appendix 1 ) . 3 . Onset weakness spasticity due ALS ≤ 2 year ( 24 month ) prior Baseline Visit . 4 . Slow vital capacity ( SVC ) measure ≥65 % predict gender , height , age screen visit . 5 . Subjects must take riluzole least 30 day , stable dose riluzole least 30 day , prior randomization ( riluzolenaïve subject permit study ) . 6 . Subjects must able swallow oral medication Screening Visit expect able swallow capsule throughout course study . 7 . Capable provide informed consent follow trial procedure . 8 . Geographically accessible site . 9 . Women must able become pregnant ( e.g . post menopausal , surgically sterile , use adequate birth control method ) duration study three month study completion . Adequate contraception include : abstinence , hormonal contraception ( oral contraception , implanted contraception , inject contraception hormonal ( patch contraceptive ring , example ) contraception ) , intrauterine device ( IUD ) place ≥ 3 month , barrier method conjunction spermicide , another adequate method . 10 . Subjects must agree take live attenuate vaccine ( include seasonal flu vaccine ) 30 day randomization , throughout duration trial 60 day follow trial . 1 . Prior use fingolimod ( Gilenya® ) . 2 . History presence cardiac condition include : 1 . Cardiovascular cerebrovascular disease previous 6 month ( eg . myocardial infarction , unstable angina , stroke ) 2 . Congestive heart failure 3 . First , second thirddegree atrioventricular block , sick sinus syndrome , serious cardiac rhythm disturbance 4 . Any history Torsades de Pointes 3 . Treatment prohibited medication within 30 day Baseline Visit : . Class Ia III antiarrhythmic medication : i.e. , Quinidine , Sotalol Includes Nuedexta b. QT interval prolong medication c. Ketoconazole d. Betablockers e. Calcium channel blocker f. Immunosuppressant medication g. Chemotherapeutic ( antineoplastic ) medication 4 . Evidence examination ECG bradycardia ( &lt; 55 bpm ) , QTc &gt; 450ms woman &gt; 430 msec men , 1st degree high conduction block . 5 . History unexplained syncope cardiac syncope . 6 . Serum AST ALT value &gt; 2.0 time upper normal limit . 7 . Active infection ( acute chronic ) . 8 . History diabetes . 9 . History macular edema uveitis . 10 . History lymphopenia . 11 . History acquire inherit immune deficiency syndrome , include leukopenia . 12 . History severe untreated chronic obstructive sleep apnea . 13 . Exposure agent currently investigation treatment patient ALS ( offlabel use investigational ) within 30 day Baseline Visit . 14 . Presence tracheostomy . 15 . Use noninvasive ventilation hypoventilation due ALS ( BiPAP ) . 16 . Presence feed tube . 17 . Presence diaphragmatic pacing system . 18 . The presence unstable psychiatric disease , cognitive impairment , dementia would impair ability subject provide inform consent , accord PI judgment , history active substance abuse within prior year . 19 . Clinically significant history unstable severe cardiac , oncologic , hepatic , renal disease , medically significant illness . 20 . Pregnant woman woman currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>Gilenya</keyword>
	<keyword>Fingolimod</keyword>
</DOC>